A study led by researchers from MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
The University of Texas at Austin is building an integrated academic medical center from the ground up, where care, research, and education operate as one system organized around the patient. This model connects prevention, diagnosis, treatment, and long-term health into a continuous experience, particularly for those with complex and serious conditions.
